Russian pharmaceutical company Generium has begun building Europe's largest biopharmaceutical plant in the country's Vladimir region, according to Russian media.
The plant is scheduled to be completed in 2018. The company partnered with Canada's ProMetic Life Science for equipment solutions. The company plans to export its production from the plant to the US, Canada and European countries. The new plant will produce biopharmaceuticals including antibodies, blood coagulants and albumin, a more effective treatment for patients with low blood volume than saline solution.
"The plant, beginning from the design stage, takes into account all modern requirements of both European regulating bodies (EMEA) and FDA, the body responsible for regulating pharmaceutical companies in the US," a representative of the company told Russian news site Lenta.ru.
In October 2014, Generium also began exporting its pharmaceutical drugs to China, after an agreement with China's largest state pharmaceutical company, Sinopharm.
